EP 0091437 A1 19831019 - THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES III, PROCESSES FOR PREPARATION AND PHARMACEUTICAL PREPARATIONS FOR SUCH COMPOUNDS.
Title (en)
THERAPEUTICALLY USEFUL TETRALIN DERIVATIVES III, PROCESSES FOR PREPARATION AND PHARMACEUTICAL PREPARATIONS FOR SUCH COMPOUNDS.
Title (de)
MEDIZINISCH WIRKSAME TETRALINABKÖMMLINGE III VERFAHREN ZUR HERSTELLUNG, SOWIE ARZNEIMITTELZUSAMMENSETZUNGEN FÜR SOLCHE VERBINDUNGEN.
Title (fr)
DERIVES III DE TETRALINE UTILES THERAPEUTIQUEMENT, PROCEDES DE PREPARATION ET PREPARATIONS PHARMACEUTIQUES CONTENANT CES COMPOSES.
Publication
Application
Priority
SE 8102922 A 19810511
Abstract (en)
[origin: WO8204042A1] Compounds of the formula <IMAGE> wherein Y is OH, R<4>COO, (R<5>)2NCOO or R<6>O, whereby R<4> is an alkyl group having 1-5 carbon atoms or a possibly substituted phenyl group, R<5> is an alkyl group having 1-5 carbon atoms and R<6> is an allyl or benzyl group, R<1> is an alkyl group having 1-3 carbon atoms, R<2> is an alkyl group having 1-6 carbon atoms, and R<3> is an alkyl group having 1-3 carbon atoms, processes and intermediates for their preparation, pharmaceutical preparations and methods of treatment employing such compounds. The compounds are useful for therapeutic purposes, especially for treatment of disorders in the central nervous system.
Abstract (fr)
Composes correspondant a la formule (FORMULE) ou Y est un OH, R4COO, (R5)2NCOO ou R6O, et R4 est un groupe alkyle possedant de 1 a 5 atomes de carbone ou un groupe phenyle eventuellement substitue, R5 est un groupe alkyle possedant de 1 a 5 atomes de carbone et R6 est un groupe alyle ou benzyle, R1 est un groupe alkyle possedant de 1 a 3 atomes de carbone, R2 est un groupe alkyle possedant de 1 a 6 atomes de carbone, et R3 est un groupe alkyle possedant de 1 a 3 atomes de carbone, procedes et produits intermediaires pour leur preparation, preparations pharmaceutiques et procedes de traitement utilisant de tels composes. Ces composes sont utiles dans des applications therapeutiques, notamment pour le traitement des troubles du systeme nerveux central.
IPC 1-7
C07C 93/14; C07C 93/26; C07C 91/28; C07C 101/42; A61K 31/135
IPC 8 full level
C07C 215/64 (2006.01); A61K 31/135 (2006.01); A61K 31/16 (2006.01); A61K 31/22 (2006.01); A61K 31/24 (2006.01); A61K 31/27 (2006.01); C07C 67/00 (2006.01); C07C 213/00 (2006.01); C07C 217/74 (2006.01); C07C 219/26 (2006.01); C07C 239/00 (2006.01); C07C 271/42 (2006.01)
IPC 8 main group level
C07C (2006.01)
CPC (source: EP)
C07C 213/00 (2013.01); C07C 213/02 (2013.01); C07C 213/06 (2013.01); C07C 213/08 (2013.01); C07C 213/10 (2013.01); C07C 215/64 (2013.01)
Designated contracting state (EPC)
AT BE CH DE FR GB LI LU NL SE
DOCDB simple family (publication)
WO 8204042 A1 19821125; AU 8455082 A 19821207; DK 576182 A 19821228; EP 0091437 A1 19831019; FI 832108 A0 19830610; FI 832108 L 19830610; JP S58500714 A 19830506; NO 830040 L 19830107
DOCDB simple family (application)
SE 8200160 W 19820510; AU 8455082 A 19820510; DK 576182 A 19821228; EP 82901557 A 19820510; FI 832108 A 19830610; JP 50158582 A 19820510; NO 830040 A 19830107